```html

Quasi‑Insulinoma (Hypoglycemia Due to Non‑Tumor Causes)

Overview

Quasi‑insulinoma is a term used to describe persistent or recurrent low‑blood‑sugar episodes that mimic insulinoma (a rare pancreatic beta‑cell tumor) but arise from non‑neoplastic mechanisms. The condition is also called non‑insulinoma pancreatogenous hypoglycemia syndrome (NIPHS) or idiopathic hypoglycemia of adulthood. Unlike true insulinoma, which accounts for <1 % of pancreatic tumors, quasi‑insulinoma results from functional dysregulation of insulin secretion, heightened insulin sensitivity, or hormonal imbalances.

It can affect both sexes and a wide age range, but most cases are reported in women of reproductive age (20‑45 years) and in patients with a history of gastric or bariatric surgery. Exact prevalence is unknown because many individuals are misdiagnosed as having “reactive” or “functional” hypoglycemia; however, studies estimate that up to 1 %–2 % of patients evaluated for unexplained hypoglycemia may have quasi‑insulinoma <sup>[1][2]</sup>.

Symptoms

Symptoms result from neuroglycopenia (insufficient glucose for the brain) and adrenergic activation (release of epinephrine, norepinephrine). They can appear suddenly after meals (post‑prandial) or, less commonly, during fasting.

• Neuroglycopenic symptoms
  • Confusion, difficulty concentrating, or “brain fog”
  • Slurred speech or difficulty forming words
  • Visual disturbances (blurred vision, double vision)
  • Seizures or loss of consciousness (rare but possible)
• Adrenergic (autonomic) symptoms
  • Palpitations or rapid heart rate
  • Shakiness, trembling, or feeling “jittery”
  • Sudden sweating (diaphoresis)
  • Hunger, often described as intense or “ravenous”
  • Anxiety, irritability, or sense of impending doom
• Other possible manifestations
  • Headache
  • Nausea or abdominal discomfort
  • Cold intolerance (especially in extremities)
  • Fatigue or lethargy after an episode

Because symptoms often mimic anxiety attacks or panic disorders, many patients experience a delay of months to years before an accurate diagnosis is made.

Causes and Risk Factors

Quasi‑insulinoma is a heterogeneous group of conditions. The most common etiologies include:

1. Post‑bariatric surgery hypoglycemia

• Roux‑en‑Y gastric bypass (RYGB) and vertical sleeve gastrectomy can cause rapid gastric emptying and an exaggerated incretin response (GLP‑1), leading to hyperinsulinemic hypoglycemia 1‑3 hours after meals.

2. Non‑insulinoma pancreatogenous hypoglycemia syndrome (NIPHS)

• Microscopic beta‑cell hyperplasia (nesidioblastosis) without a discrete tumor.
• Often associated with genetic mutations (e.g., KCNJ11 or ABCC8) that increase beta‑cell activity.

3. Medication‑induced hypoglycemia

• High‑dose sulfonylureas or meglitinides used for type 2 diabetes.
• Beta‑blockers, quinine, certain antibiotics (e.g., trimethoprim‑sulfamethoxazole), and alcohol‑containing preparations.

4. Endocrine disorders

• Adrenal insufficiency (primary or secondary).
• Hypothyroidism causing increased insulin sensitivity.
• Growth hormone deficiency.

5. Critical illnesses and organ failure

• Severe liver disease, renal failure, or sepsis can impair gluconeogenesis.

Risk Factors

• History of bariatric surgery (especially RYGB).
• Female gender and age 20‑45 years (for NIPHS).
• Family history of congenital hyperinsulinism or endocrine tumors.
• Use of insulin‑secretagogue drugs.
• Autoimmune conditions that may affect adrenal or pituitary function.

Diagnosis

Because hypoglycemia can have many causes, a systematic approach is essential. The diagnostic work‑up typically follows the “Whipple’s triad”:

1. Symptoms suggestive of hypoglycemia.
2. Documented low plasma glucose (< 55 mg/dL or 3.0 mmol/L) at the time of symptoms.
3. Resolution of symptoms after glucose administration.

Step‑by‑step Evaluation

1. Detailed History & Physical Examination

• Timing of episodes (fasting vs. post‑prandial).
• Recent surgeries, medications, alcohol intake.
• Family history of endocrine tumors.

2. Laboratory Tests During an Episode

Test	Typical Finding in Quasi‑insulinoma
Plasma glucose	<55 mg/dL (3.0 mmol/L)
Insulin	Inappropriately normal or elevated (> 3 µIU/mL)
C‑peptide	Elevated (> 0.6 ng/mL) – distinguishes endogenous from exogenous insulin
Pro‑insulin	Often increased
β‑hydroxybutyrate	Suppressed (≤ 0.4 mmol/L) indicating insulin effect
Oral hypoglycemic screen	Negative (rules out sulfonylurea ingestion)

3. Provocative Testing

• 72‑hour fast – gold standard for insulinoma; many quasi‑insulinoma patients will develop hypoglycemia earlier (often within 24 h) with similar labs.
• Mixed‑Meal Tolerance Test (MMTT) – useful for post‑prandial hypoglycemia; a drop in glucose < 55 mg/dL at 2‑3 h with high insulin supports the diagnosis.

4. Imaging

• CT or MRI of the abdomen – to exclude insulinoma or pancreas masses.
• Endoscopic ultrasound (EUS) – higher sensitivity for small tumors.
• If imaging is negative but suspicion remains, selective arterial calcium stimulation with hepatic venous sampling can localize hyperfunctioning beta‑cells.

5. Additional Hormonal Assessment

• Morning cortisol and ACTH (adrenal insufficiency).
• TSH, free T4 (hypothyroidism).
• Growth hormone (GH) axis if clinically indicated.

Diagnosis is confirmed when biochemical evidence of excessive insulin (or insulin‐like activity) is present, imaging does not reveal a tumor, and an alternative cause (medication, critical illness) is excluded.

Treatment Options

Management is individualized, focusing on correcting the underlying pathophysiology while preventing hypoglycemic episodes.

1. Lifestyle and Dietary Modifications

• Frequent, small meals – 5–6 meals/snacks per day, each containing protein, complex carbs, and healthy fats.
• Low‑glycemic‑index (GI) carbohydrates – reduce rapid glucose spikes and subsequent insulin surges.
• Avoid simple sugars (sodas, candies) and high‑glycemic foods that trigger post‑prandial spikes.
• Protein‑rich bedtime snack (e.g., Greek yogurt, nuts) to sustain glucose overnight.
• For post‑bariatric patients, carbohydrate restriction (≤ 30 g per meal) and “protein‑first” eating order is recommended.

2. Pharmacologic Therapy

Medication	Mechanism	Typical Dose	Key Side Effects
Diazoxide	Opens potassium channels → suppresses insulin release	5–10 mg/kg/day divided q6‑8h	Fluid retention, hypertrichosis, GI upset
Octreotide (short‑acting) or Lanreotide (long‑acting)	Somatostatin analog → inhibits insulin and incretin secretion	Short‑acting 50–100 µg SC q8h; Lanreotide 90 mg SC every 4 weeks	Steatorrhea, gallstones, glucose intolerance
Calcium channel blockers (e.g., Verapamil)	Reduces calcium influx into beta‑cells, lowering insulin release	120–240 mg PO daily	Hypotension, constipation
GLP‑1 receptor antagonists (e.g., Exendin(9‑39) – investigational)	Blocks GLP‑1‑mediated insulin surge	Clinical trials only	Limited data

Medication choice depends on severity, tolerance, and presence of comorbidities. Diazoxide is often first‑line for NIPHS; somatostatin analogs are preferred after bariatric surgery.

3. Interventional / Surgical Options

• Partial pancreatectomy – removal of the head or distal pancreas; effective in refractory NIPHS but carries risk of exocrine insufficiency and diabetes.
• Pancreatic duct ligation or radiofrequency ablation – emerging minimally invasive techniques under investigation.
• For severe post‑bariatric hypoglycemia, reversal of the gastric bypass or conversion to a less malabsorptive procedure may be considered.

4. Acute Management of an Episode

1. Consume 15‑20 g of fast‑acting carbohydrate (e.g., glucose tablets, regular soda).
2. Re‑check glucose after 15 minutes; repeat if still < 55 mg/dL.
3. If unable to swallow, administer glucagon 1 mg IM or subcutaneously.
4. Seek emergency care if consciousness does not improve within 30 minutes.

Living with Quasi‑insulinoma (hypoglycemia due to non‑tumor causes)

Long‑term success hinges on education, routine monitoring, and collaboration with a multidisciplinary team (endocrinologist, dietitian, surgeon, psychologist).

Daily Management Tips

• Carry glucose source at all times – tablets, gel, or sugary snack.
• Use a continuous glucose monitor (CGM) when available; alerts help prevent severe drops.
• Maintain a food and symptom diary to identify trigger patterns.
• Schedule regular follow‑up labs (fasting insulin, C‑peptide) every 6–12 months.
• Stay hydrated; dehydration worsens hypoglycemia.
• Engage in moderate exercise after meals rather than on an empty stomach.
• If you have a bariatric surgery background, consider a nutrition‑focused support group to share strategies.

Psychosocial Aspects

Recurrent hypoglycemia can cause anxiety, depression, and fear of eating. Referral to a mental‑health professional familiar with chronic metabolic disorders is recommended.

Prevention

Because quasi‑insulinoma stems from functional dysregulation rather than a modifiable lifestyle factor, primary prevention focuses on reducing known triggers:

• Before bariatric surgery, discuss the risk of post‑operative hypoglycemia with your surgeon; consider alternatives (e.g., sleeve gastrectomy) if high risk.
• Avoid unnecessary use of insulin‑secretagogue drugs; if required, use the lowest effective dose.
• Screen for adrenal, thyroid, or pituitary insufficiency when unexplained hypoglycemia appears.
• Educate family members on recognizing and treating hypoglycemia.

Complications

If left untreated or poorly controlled, quasi‑insulinoma can lead to:

• Severe neuroglycopenic injury – seizures, permanent cognitive deficits.
• Accidents or injuries due to loss of consciousness.
• Cardiovascular events (arrhythmias) triggered by catecholamine surges.
• Weight loss or malnutrition from fear of eating.
• Development of diabetes mellitus after extensive pancreatic resection.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Hypoglycemia.” https://www.mayoclinic.org (accessed 2024).
2. Cleveland Clinic. “Non‑insulinoma pancreatogenous hypoglycemia syndrome (NIPHS).” https://my.clevelandclinic.org (2023).
3. American Diabetes Association. “Post‑bariatric hypoglycemia.” Diabetes Care, 2022;45(8):1790‑1798.
4. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Hyperinsulinism.” https://www.niddk.nih.gov (2023).
5. World Health Organization. “Guidelines for the management of hypoglycemia.” WHO, 2021.

```